No Data
No Data
HOSHIZAKI (HSHIF) Gets a Buy From UBS
Toa Pharmaceutical, NGK, and others (additional) Rating
Rating upgrades - Bullish code stock name, securities company, previous rating, and updated rating are as follows: <5201> AGC Nomura "Neutral" to "Buy"; <6586> Makita Daiwa "2" to "1"; <7164> Zenkoku Hosho SBI "Neutral" to "Buy." Rating downgrades - Bearish code stock name, securities company, previous rating, and updated rating are as follows:
Goldman Sachs Reaffirms Their Hold Rating on HOSHIZAKI (HSHIF)
Attention is focused on the market reaction to Kioxia's earnings report.
[Opening Comments on Stock Market] The Japanese stock market on the 18th is likely to open lower, but after the initial selling pressure eases, the market is expected to focus on semiconductor and AI-related stocks. On the 15th, the U.S. market saw the NY Dow drop by 537 points and Nasdaq fall by 410 points. A lack of progress in negotiations toward ending hostilities between the U.S. and Iran weighed on sentiment, with WTI crude oil futures rising to over $105 per barrel. The CME Nikkei 225 futures were down 215 points from Osaka at 61,825 yen. The yen exchange rate was 1 dollar...
Terumo reported an 11.8% increase in operating profit to 176.3 billion yen for the fiscal year ending March 26, and forecasts a 27.3% increase to 224.5 billion yen for the fiscal year ending March 27.
Terumo <4543> announced its consolidated financial results for the fiscal year ending March 2026, reporting a 9.2% year-on-year increase in revenue to 1.131877 trillion yen and an 11.8% rise in operating income to 176.32 billion yen. In the cardiovascular company segment, overseas operations grew across all businesses, particularly driven by the interventional systems business. Additionally, in the Blood and Cell Technologies Company segment, global expansion of the plasma innovation business accelerated in North America, contributing to overall growth.
Hoshizaki Completes Restricted Share Disposal With Minor Adjustment After Forfeiture